Vandortuzumab, this novel protein, represents the intriguing clinical compound targeting CD40, the key receptor involved in immune response. The mechanism of action requires modulating CD40 pathway, possibly resulting to lower growth and improved susceptibility to additional oncology treatments. Ear

Andecaliximab, also known as GS-5745, represents a valuable research tool within the field of immune studies . This humanized monoclonal immunoglobulin selectively interacts with CD40 ligand (CD40L), a crucial substance involved in inflammatory responses. By inhibiting CD40L binding with its recepto